Genomic profiling of cancer: What next?

Journal of Clinical Oncology

Volumn 23, Issue 29, 2005, Pages 7253-7256

  Workman, Paul ^a   Johnston, Patrick G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GENETICS; CANCER SURVIVAL; EDITORIAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TECHNOLOGY; GENETIC POLYMORPHISM; GENOME IMPRINTING; HETEROZYGOSITY; HUMAN; MICROARRAY ANALYSIS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; DNA MICROARRAY; GENETICS; GENOME; NEOPLASM; NOTE;

GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 33644671990     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.9792     Document Type: Editorial

References (28)

1. Walgren RA, Meucci MA, McLeod HL: Pharmacogenomic discovery approaches: Will the real genes please stand up? J Clin Oncol 23:7342-7349, 2005
2. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
3. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
4. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
5. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73, 2005
6. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792, 2005
7. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
8. Bardelli A, Parsons DW, Silliman IM, et al: Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300:949, 2003
9. Samuels Y, Wang Z Bardelli N, et al: High frequency of mutations of the PIK3CA gene in the human cancer. Science 304:554, 2004
10. Workman P: Genomics and the second golden era of cancer research. Mol BioSystems. 1:17-27, 2005
11. International Human Genome Sequencing Consortium: Finishing the euchromatic sequence of the human genome. Nature 431:931-945, 2004
12. Futreal PA, Coin L, Marshall M, et al: A census of human cancer genes. Nat Rev Cancer 4:177-183, 2004
13. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med 10:789-799, 2004
14. Simon R: A roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23:7332-7341, 2005
15. Brenton J, Carey LA, Ahmed AA, et al: Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol, in press
16. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumors. Nature 406:747-752, 2000
17. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
18. Wang Y, Klijn JG, Zhang Y, et al: Gene expression profiles to predict distant metastasis of lymph node negative primary breast cancer. Lancet 365:671-679, 2005
19. Gianni L, Zambetti M, Clark K, et al: Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23:7265-7277, 2005
20. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
21. Espinosa E, Fresno Vara JA, Redondo A, et al: Breast cancer prognosis determined by gene expression profiling: A quantitative RT-PCR study. J Clin Oncol 23:7278-7285, 2005
22. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
23. Sieben N, Oosting J, Flanagan A, et al: Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. J Clin Oncol 23:7257-7264, 2005
24. Spinola M, Vera L, Pignatiello C, et al: The functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 23:7307-7311, 2005
25. Bilke S, Chen QR, Westerman F, et al: Inferring a tumor progression model for neuroblastoma from genomic data. J Clin Oncol 23:7322-7331, 2005
26. Grundy PE, Breslow NE, Li S, et al: Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable histology Wilms tumor: A report from the National Wilms Tumor Study Group. J Clin Oncol 23:7312-7321, 2005
27. Chen C-N, Lin J-J, Chen JJW, et al. Gene expression profile predicts patient survival of gastric cancer after surgical resection. J Clin Oncol 23:7286-7295, 2005
28. Agnelli L, Bicciato S, Mattioli M, et al: Molecular classification of multiple myeloma: A distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol 23:7296-7306, 2005